Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment

被引：49

作者：

Casteele, N. Vande ^{[1
]}

Ballet, V. ^{[2
]}

Van Assche, G. ^{[2
]}

Rutgeerts, P. ^{[2
]}

Vermeire, S. ^{[2
]}

Gils, A. ^{[1
]}

机构：

[1] Katholieke Univ Leuven, Dept Pharmaceut Sci, Lab Pharmaceut Biol, B-3000 Louvain, Belgium

[2] Univ Hosp Leuven, Dept Gastroenterol, Louvain, Belgium

来源：

GUT | 2012年 / 61卷 / 02期

关键词：

CROHNS-DISEASE;

D O I：

10.1136/gut.2010.236869

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

引用

页码：321 / 321

页数：1

共 3 条

[1]

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].

Baert, F ;

Noman, M ;

Vermeire, S ;

Van Assche, G ;

D'Haens, G ;

Carbonez, A ;

Rutgeerts, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608

[2]

The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful [J].

Ben-Horin, Shomron ;

Yavzori, Miri ;

Katz, Lior ;

Kopylov, Uri ;

Picard, Orit ;

Fudim, Ella ;

Coscas, Daniel ;

Bar-Meir, Simon ;

Goldstein, Itamar ;

Chowers, Yehuda .

GUT, 2011, 60 (01) :41-48

[3]

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease [J].

Vermeire, Severine ;

Noman, Maja ;

Van Assche, Gert ;

Baert, Filip ;

D'Haens, Geert ;

Rutgeerts, Paul .

GUT, 2007, 56 (09) :1226-1231

← 1 →